Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- METI Recommends Modernization of Trade Practices in Japan
September 17, 2001
- Kureha, Sankyo to Codevelop Kremezin in US
September 17, 2001
- BULLETIN
September 17, 2001
- Wholesalers Should Charge for Immediate PMS Services: Mr Masuda of Kuraya Sanseido
September 17, 2001
- OTC NEWS IN BRIEF
September 17, 2001
- BUSINESS NEWS IN BRIEF
September 17, 2001
- Cholesterol Levels in Postmenopausal Women to Be Surveyed
September 17, 2001
- CORPORATE ROUNDUP NEWS IN BRIEF
September 17, 2001
- DIAGNOSTIC NEWS IN BRIEF
September 17, 2001
- Healthcare Reform: 30% Copayment for the Insured to Be Focused on
September 17, 2001
- Thorough Quality Control for Imported Medical Devices Called For by PMSB
September 17, 2001
- Hodanren Opposes Raising the Age Limit to 75 for Elderly Healthcare Services
September 17, 2001
- PMSB Budget Related to Medical Devices Focuses on Quality, Prioritization of Review
September 17, 2001
- 3 New Drugs Including Biapenem Recommended for Approval
September 17, 2001
- Enforcement of US/EC MRA Expected to Be Delayed: FDA Officer
September 17, 2001
- NDA Data Disclosure Procedures Notified
September 17, 2001
- MEDICAL DEVICE NEWS IN BRIEF
September 17, 2001
- JETRO Looks Into Social Security Systems in Major Countries
September 17, 2001
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
September 17, 2001
- REGULATORY NEWS IN BRIEF -1-
September 17, 2001
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…